explore -WSS

explore

author：leisure time 2025-08-11 07:58:55 - browse：49364

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： AMAs digital advisors table RPM coding reform proposal, again

WSS

Long Covid research funding gets a major boost from NIH

What would happen to your eyes if you looked at the solar eclipse?

With FDA staff opposed to Sarepta therapy, top official intervened

Death of patient in Alzheimer’s trial raises question of possible risks

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Death of patient in Alzheimer’s trial raises question of possible risks

explore

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

What would happen to your eyes if you looked at the solar eclipse?

Alkermes shareholders re

Artificial intelligence use in health care faces greater scrutiny in 2024

In Memoriam: Notable people who died in 2023

The battle over the Brookhaven Landfill on Long Island

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Congress considering partial increase for doctor pay in Medicare

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

STAT's guide to the next generation of CAR

explore

The strategy behind pharma's lawsuits over drug pricing reform

Long Covid research funding gets a major boost from NIH

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

ACIP vaccine advisory panel sees its vacancies filled

CDC concerned about possible undetected monkeypox spread in U.K.

focus

Wikipedia

hotspot

hotspot